BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zibotentan + Dapagliflozin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zibotentan + Dapagliflozin\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06087835-536@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Zibotentan + Dapagliflozin: Phase 3 readout est. (NCT06087835)
DESCRIPTION:Zibotentan + Dapagliflozin\, phase 3\, Chronic Kidney Disease.\
 nStudy: Study to Investigate Efficacy\, Safety\, and Tolerability of Zibot
 entan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic
  Kidney Disease and High Proteinuria (ZENITH High Proteinuria)\nEstimated 
 primary completion: 18 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06087835
URL:https://assetmemo.bio/drug/zibotentan-dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
